Zomedica Reports NYSE American Delisting and $55.8M Impairment Amid Widening Losses in 2025 Annual Report
summarizeSummary
Zomedica Corp. reported its delisting from NYSE American to OTCQB in March 2025, leading to a $55.8 million impairment charge and a widened net loss of $81.9 million for the year, despite a 17% revenue increase.
check_boxKey Events
-
NYSE American Delisting
The company's common shares were delisted from NYSE American on March 4, 2025, due to a low share price, and now trade on the OTCQB Market under the symbol 'ZOMDF'.
-
Significant Impairment Charges
Zomedica recognized $55.8 million in non-cash impairment charges in 2025, primarily due to the decline in market capitalization following the delisting. This included $45.6 million for goodwill, fully impairing it, and $8.3 million for intangible assets.
-
Widening Net Loss
The net loss for the year ended December 31, 2025, increased to $81.9 million, up 74% from $47.0 million in 2024, driven largely by the impairment expense.
-
Revenue Growth and Reduced Cash Burn
Despite the losses, revenue grew 17% to $32.0 million in 2025, and net cash used in operating activities decreased by 25% to $17.6 million.
auto_awesomeAnalysis
Zomedica Corp.'s 2025 annual report reveals significant financial challenges, most notably its delisting from the NYSE American to the OTCQB market in March 2025 due to a low share price. This event triggered a substantial non-cash impairment charge of $55.8 million, which fully impaired the company's goodwill and impacted other intangible assets and property/equipment. The company's net loss widened considerably to $81.9 million in 2025, and its accumulated deficit grew to $299.8 million. While revenue increased by 17% to $32.0 million and cash used in operating activities decreased, the overall financial picture indicates severe distress and a need for continued operational improvement and capital management. The company's ability to utilize its significant net operating loss carryforwards is also limited by prior ownership changes and the need to generate future taxable income.
At the time of this filing, ZOMDF was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $124.9M. The 52-week trading range was $0.04 to $0.16. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.